A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess safety, efficacy, and tolerability of pramlintide dose escalation with proactive mealtime insulin reduction, followed by insulin optimization, in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS—This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin. During initiation, pramlintide was escalated from 15 to 60 μg/meal (15-μg increments) with recommended reductions (30–50%) in mealtime insulin. Insulin was subsequently adjusted to optimize glycemic control. End points included safety and change in HbA1c (A1C), postprandial glucose, insulin, weight, and tolerability. RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased comparably (pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5% [−0.63 to −0.35]). Pramlintide treatment significantly reduced postprandial glucose excursions (incremental area under the curve [AUC]0–3h: pramlintide −175 ± 40, placebo −64 ± 38 mg · h−1 · dl−1; P < 0.0005) and weight (pramlintide −1.3 ± 0.30, placebo +1.2 ± 0.30 kg; P < 0.0001). At week 29, insulin dose decreased by 28 and 4% in pramlintide- and placebo-treated groups, respectively. Nausea, reported by 63 and 36% of patients in pramlintide and placebo groups (P < 0.01), respectively, was predominately mild to moderate in intensity. Severe hypoglycemia rates were low in both groups (pramlintide 0.57 ± 0.09, placebo 0.30 ± 0.06 event rate/patient-year; P < 0.05), with increased rates observed in patients remaining at 30 μg pramlintide. CONCLUSIONS—Pramlintide dose escalation with reduced mealtime insulin was effective during therapy initiation in patients with type 1 diabetes. While both groups experienced equivalent A1C reductions relative to placebo, pramlintide-treated patients experienced reductions in postprandial glucose excursions and weight, not achievable with insulin therapy alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ultrarapid insulins (ie, faster aspart, lispro aabc) have demonstrated earlier time of onset and action but similar duration of action.1165”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1165]
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Ceriello, A., & Motz, E. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000122852.22604.78 · Cited by 1,378
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873
Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90605-w · Cited by 807
Epidemiology of severe hypoglycemia in the diabetes control and complications trial
(1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80085-z · Cited by 807
de Vegt, F., Dekker, J. M., Ruhé, H. G., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1999) · Diabetologia · doi:10.1007/s001250051249 · Cited by 613
Balkau, B., Shipley, M., Jarrett, R. J., Pyörälä, K., Pyörälä, M., Forhan, A., & Eschwège, E. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 598
Purnell, J. Q., Hokanson, J. E., Marcovina, S. M., Steffes, M. W., Cleary, P. A., & Brunzell, J. D. (1998) · JAMA · doi:10.1001/jama.280.2.140 · Cited by 469
Should minimal blood glucose variability become the gold standard of glycemic control?
Hirsch, I. B., & Brownlee, M. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.10.001 · Cited by 405
Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial
The DCCT Research Group (1988) · Diabetes Care · doi:10.2337/diacare.11.7.567 · Cited by 345
Cited by
Items 101–174 of 174
Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy
Merlino, D. J., Blomain, E. S., Aing, A., & Waldman, S. A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030763 · Cited by 13
Primer on Pramlintide, an Amylin Analog
Traina, A. N., & Kane, M. P. (2011) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721711403011 · Cited by 13
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Biester, T., Kordonouri, O., & Danne, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13659 · Cited by 13
King, A. B. (2009) · Endocrine Practice · doi:10.4158/ep.15.3.229 · Cited by 13
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Abu‐Zaid, A., Altowairqi, A. K., Dissanayaka, T. D., Oganesyan, A., Bhagavathula, A. S., Alhabeeb, H., Baradhwan, A., Alomar, S. A., & Tom, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105456 · Cited by 12
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Ang, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
Pramlintide Reduces the Risks Associated with Glucose Variability in Type 1 Diabetes
Kovatchev, B. P., Crean, J., & McCall, A. L. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0295 · Cited by 11
Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases
Wang, A., Guan, B., Zhang, H., & Xu, H. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106983 · Cited by 10
SGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Physiological models for artificial pancreas development
VISENTIN, R., Schiavon, M., Basu, R., Basu, A., Man, C. D., & Cobelli, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815655-1.00015-6 · Cited by 10
Association between subclinical hypothyroidism and diabetic nephropathy in type 2 diabetes
Nsr-Allah, A. A.-E. M., El-Fatah, A. H. A., Azab, M., & Fawzi, M. M. (2018) · The Egyptian Journal of Internal Medicine · doi:10.4103/ejim.ejim_25_18 · Cited by 8
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
King, A. B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0096 · Cited by 7
Kruger, D. F., Aronoff, S. L., & Edelman, S. V. (2007) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721707299766 · Cited by 7
Self-citationPramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2006) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.1.9 · Cited by 7
Self-citationLeahy, J. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70039-8 · Cited by 7
Melander, S. A., Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16329 · Cited by 6
Recent Advances in Management of Diabetes Mellitus
Ganie, M. A., & Kotwal, S. K. (2012) · Cited by 6
Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
Monnier, L. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0454 · Cited by 6
Andersen, G., Eloy, R., Heise, T., Gaudier, M., Mégret, C., Seroussi, C., Chan, Y., Soula, O., Riddle, M. C., & DeVries, J. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15827 · Cited by 5
Pharmacotherapy of hyperglycemia in type 2 diabetes mellitus
Weinert, L. S., Camargo, E. G., & Silveiro, S. P. (2010) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 5
Pharmacotherapy for obesity: a field in crisis?
Fenske, W. K., Parker, J., & Bloom, S. R. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.50 · Cited by 5
A Review of Pramlintide in the Management of Diabetes
Messer, C., & Green, D. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2369 · Cited by 5
Small steps forward: Adjunctive therapy for T1D
Bloomgarden, Z. T., & Schatz, D. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13326 · Cited by 4
Khaliq, A., Chughtai, M. F. J., Iqbal, J., Nawaz, H., Ahsan, S., Mehmood, T., Liaqat, A., Nadeem, M., Sameed, N., Saeed, K., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-76320-6_16 · Cited by 4
The Rationale for Prandial Glycemic Control in Diabetes Mellitus
Perkins, J. M., & Davis, S. N. (2007) · Insulin · doi:10.1016/s1557-0843(07)80016-9 · Cited by 4
Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity
Chung, C. W., & Kim, J. (2026) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes25085 · Cited by 3
Adjunct Therapies In Type 1 Diabetes
Dandona, P., Kuhadiya, N. D., Ghanim, H., & Chaudhuri, A. (2016) · Endocrine Practice · doi:10.4158/ep151113.co · Cited by 3
Pramlintide: profile of an amylin analog
Lebovitz, H. E. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.50 · Cited by 3
Lush, C. W., Darsow, T., Zhang, B., Lorenzi, G. M., & Frías, J. P. (2007) · Insulin · doi:10.1016/s1557-0843(07)80060-1 · Cited by 3
Self-citationType 2 treatments for type 1 diabetes
Bloomgarden, Z. T., & Ning, G. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12430 · Cited by 3
Insulin Pumps and Artificial Pancreas
Taleb, N., Gingras, V., & RABASA-LHORET, R. P. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65407-7 · Cited by 3
SNAITH, J. R., Narongkiatikhun, P., Bjornstad, P., Greenfield, J. R., & Tommerdahl, K. L. (2025) · doi:10.2337/figshare.29575130 · Cited by 3
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Skyler, J. S. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_18 · Cited by 2
Pramlintide Acetate in the Treatment of Type 2 Diabetes
Edelman, S. V., Schroeder, B. E., & Frías, J. P. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-14 · Cited by 2
Self-citationAn overview of non-insulin adjunctive therapies for Type 1 diabetes
Ballav, C., & Gough, S. C. L. (2014) · Diabetes Management · doi:10.2217/dmt.14.38 · Cited by 2
New treatments of diabetes: The β-amylin agonists
Lebovitz, H. E. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.02.015 · Cited by 2
Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes
Lingow, S. E., Burke, S. D., Brooks, A. D., & Rafferty, P. S. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0058 · Cited by 2
Considering Pramlintide Therapy for Postprandial Blood Glucose Control
Childs, B. P., Kesty, N. C., KLEIN, E. J., Rubin, R. R., & Wick, A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.2.108 · Cited by 2
Next-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Pharmacologic Approaches to Type 2 Diabetes and Obesity in Children and Adolescents
Pongsuwan, P. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-256-8_12 · Cited by 1
Avancées technologiques et traitement du diabète
Roy‐Fleming, A., & Taleb, N. (2018) · Nutrition, science en évolution · doi:10.7202/1048943ar · Cited by 1
The Underutilization of Pramlintide as Adjunct Therapy in Type 1 and Type 2 Diabetes
Smarr, T., & Clements, J. N. (2023) · ADCES in Practice · doi:10.1177/2633559x221150809 · Cited by 1
Combination Therapy for Treatment of Type 2 Diabetes
McCall, A. L. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-16 · Cited by 1
Gastrointestinal Hormones and Obesity
Wang, Y., & Kokkotou, E. G. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1607-5_6
Self-citationMonnier, L. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0507
What's new in…..obesity. Neuroendocrinology of obesity and the potential for new treatments
Field, B. C. T. (2012) · Medicine · doi:10.1016/j.mpmed.2012.10.003
Pramlintide in the Management of Obesity
Jones, M. C., DeBellis, H. F., & Barefield, K. L. (2010) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s4021
Amylin dual action: a second gluco regulatory β-cell hormone, treatment and cause for the diabetes
Tripathi, A. S., Wadhwani, P. J., Majumder, P. M., Chandewar, A. V., Marathe, S., & Mahajan, P. G. (2014) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-014-0203-1
Preventing severe hypoglycemia in children and adolescents with type 1 diabetes
Ly, T. T. (2013) · UWA Profiles and Research Repository (UWA)
Glucose control with non-insulin based therapies for type 1 diabetes
Narendran, P., & Smyth, T. (2016) · Nurse Prescribing · doi:10.12968/npre.2016.14.1.24
Artificial pancreas development in type 1 diabetic patients
Boscari, F. (2018) · Padua@research (University of Padova)
Lima, L. M. T. R., de Araújo, T. S., & Almeida, M. S. (2021) · Peptide Science · doi:10.1002/pep2.24252
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282c3a898
(2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280d5f7e9
Current literature in diabetes
(2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.754
Dose escalation of pramlintide improves its tolerability and efficacy
(2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0360
Oroko, M., Llano, A., & Fisher, M. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch13
MESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1
Litwak, L., Martín, C. G., Garrido, N., Koleff, C. K., Canda, M. E., Burgos, M. A., Bertollo, N., Scaliti, M. G., Blanco, M. A., Calvo, M. L., et al. (2015) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v49i3.633
Treatment of Obesity in Individuals with Type 1 Diabetes
Almehthel, M. S., & Alshehri, A. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2332
Pawar, A. D., Rohile, S. B., & D., S. S. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29628
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch14
Weight Loss Medications and the Metabolic Syndrome
Buckley, L. L., & Berressen, D. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-192-5_16
Chu, L., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Figshare · doi:10.6084/m9.figshare.13240350
Ćirić, V. (2023) · National Repository of Dissertations in Serbia
Föchterle, S. (2020) · University Library Linz repository (Johannes Kepler Universitat Linz)
Obesity in Adults with Type 1 Diabetes Mellitus
Batman, A., Sulu, C., YAZICI, D., Boyle, L., McGowan, B. M., & Yumuk, V. (2026) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes26001
New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01921-0
Metadata
- Authors
- Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O.
- Affiliations
- Division of Diabetes/Metabolism, San Diego VA Medical Center, San Diego, California
- Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-10-01
- Volume
- 29
- Issue
- 10
- Pages
- 2189-2195
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2126969411
- Cited by
- 166
- References
- 25
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 8 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 15 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- type 1 diabetes, intensive insulin therapy, glycemic control, HbA1c, postprandial blood glucose, weight loss, nausea, hypoglycemia, GLP-1 receptor agonists, dose escalation, weight gain, weight loss maintenance
- MeSH terms
- Adult, Amyloid, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Eating, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.